Pharmacological Properties of CY 216 and of Its ACLM and BCLM Components in the Rabbit

 

PDF Download Buy Article Permissions and Reprints

Summary

This study compares some in vivo pharmacological properties of CY 216 and of its ACLM and BCLM components having a molecular weight above and below 5.4 kDa respectively. The anti-factor Xa/anti-thrombin ratio of these compounds determined in a rabbit plasma system were 2.5 and 1.2 for CY 216 and ACLM respectively while BCLM was devoid of anti-thrombin effect. After bolus intravenous injection, continuous infusion and subcutaneous administration, the clearances of anti-factor Xa activity generated by ACLM were, on the average, 2 and 1.5 times higher than those generated by BCLM and CY 216 respectively. The clearances of the anti-thrombin activity were comparable for CY 216 and ACLM, and higher than those of the antifactor Xa activity. The duration of the antithrombotic effect was investigated in the Wessler model after a single subcutaneous injection of 1000 anti-factor Xa units of one of the compounds. Using thromboplastin as thrombogenic stimulus, the most efficient agent was ACLM and the antithrombotic activity was essentially correlated to the circulating anti-thrombin activity. Using human serum as thrombogenic stimulus, ACLM and BCLM were more efficient than CY 216 and the antithrombotic activity was mainly correlated to the anti-factor Xa activity. The ability of the 3 compounds to inhibit venous thrombosis growth was compared: they were found equipotent and the antithrombotic effect was independent of the anti-thrombin activity. The pro-haemorrhagic properties were compared in the rabbit ear model. The activity of the 3 compounds were comparable and significantly less prohaemorrhagic than unfractionated heparin. These results suggest that the haemorrhagic potential of unfractionated heparin and of LMWH is independent of the anti-thrombin and anticoagulant activity, but related to the molecular weight. These observations indicate that factor Xa inhibition is a valuable target to prevent and to treat venous thrombosis and that the anti-factor Xa activity of a low molecular weight heparin (LMWH) largely contributes to its antithrombotic effect.

• References

• 1 Fareed J, Walenga JM, Hoppensteadt D, Huan X, Nonn R. Biochemical and pharmacologic inequivalence of low molecular weight heparins. Ann NY Acad Sci 1989; 556: 333-353
  CrossrefPubMedGoogle Scholar
• 2 Lane DA, Denton J, Flynn AM, Thunberg L, Lindhal U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 1984; 218: 725-732
  CrossrefPubMedGoogle Scholar
• 3 Hemker HC, Beguin S. A rational approach to heparins. Nouv Rev Fr He-matol 1992; 34: 5-9
  PubMedGoogle Scholar
• 4 Beguin S, Wielders S, Lormeau JC, Hemker HC. The mode of action of CY 216 and CY 222 in plasma. Thromb Haemost 1992; 67: 33-41
  Article in Thieme ConnectPubMedGoogle Scholar
• 5 Schoen P, Lindhout Y, Franssen J, Hemker HC. Low molecular weight heparin-catalyzed inactivation of factor Xa and thrombin by anti-thrombin III. Effect of platelet factor 4. Thromb Haemost 1991; 66: 435-441
  Article in Thieme ConnectPubMedGoogle Scholar
• 6 Boneu B, Caranobe C, Saivin S, Dol F, Sie P. Pharmacokinetics of heparin and of dermatan sulfate: clinical implications. In: Heparin and Related Polysaccharides. Lane DA, Bjork I, Lindhal U (eds). Plenum Press, New York 1992: 237-247
  PubMedGoogle Scholar
• 7 Caranobe C, Petitou M, Dupouy D, Gabaig AM, Sie P, Buchanan MR, Boneu B. Heparin fraction with high and low affinities to anti-thrombin III are cleared at different rates. Thromb Res 1986; 43: 635-641
  CrossrefPubMedGoogle Scholar
• 8 Barzu T, Van Rijn JLML, Petitou M, Molho P, Tobelem G, Caen J. Endothelial binding sites for heparin. Biochem J 1986; 238: 847-854
  CrossrefPubMedGoogle Scholar
• 9 Briant L, Caranobe C, Saivin S, Sie P, Bayrou B, Houin G, Boneu B. Unfractionated heparin and CY 216: pharmacokinetics and bioavailabilities of the anti-factor Xa and anti-thrombin effects after intravenous and subcutaneous injection in the rabbit. Thromb Haemost 1989; 61: 348-353
  Article in Thieme ConnectPubMedGoogle Scholar
• 10 Leizorovicz A, Haugh MC, Chapuis FR, Samama MM, Boissel JP. Low molecular weight heparin in prevention of perioperative thrombosis. Br Med J 1992; 305: 913-920
  CrossrefPubMedGoogle Scholar
• 11 Leizorovicz A, Simonneau G, Decousus H. Comparison of low molecular weight heparin and unfractionated heparin in the treatment of DVT: a metaanalysis. Thromb Haemost 1993; 69: 647 (Abst)
  PubMedGoogle Scholar
• 12 Nordeman B, Bjork I. Binding of low-affinity and high-affinity heparin to anti-thrombin. Ultraviolet difference spectroscopy and circular dichroism studies. Biochemistry 1987; 17: 3339-3344
  PubMedGoogle Scholar
• 13 Barrowcliffe TW, Curtis A, Johnson E, Thomas DP. An international standard for low molecular weight heparin. Thromb Haemost 1988; 60: 1-8
  Article in Thieme ConnectPubMedGoogle Scholar
• 14 Gomeni R. Pharm: an interactive graphic program for individual and population pharmacokinetic parameters estimation. Comput Biomed Res 1984; 14: 25-34
  PubMedGoogle Scholar
• 15 Wessler S, Reimer SM, Sheps MC. Biologic assay of a thrombosis inducing activity in human serum. J Appl Physiol 1959; 14: 943-946
  CrossrefPubMedGoogle Scholar
• 16 Amar J, Caranobe C, Petitou M, Sie P, Boneu B. Antithrombotic potencies of heparins in relation to their anti-factor Xa and anti-thrombin activities: an experimental study in two models of thrombosis in the rabbit. Br J Haematol 1990; 76: 94-100
  CrossrefPubMedGoogle Scholar
• 17 Chiu HM, Hirsh J, Yung WL, Regoeczi E, Gent M. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 1977; 49: 171-184
  PubMedGoogle Scholar
• 18 Carrie D, Caranobe C, Gabaig AM, Larroche M, Boneu B. Effects of heparin, dermatan sulfate and of their association on the inhibition of venous thrombosis growth in the rabbit. Thromb Haemost 1992; 68: 637-641
  Article in Thieme ConnectPubMedGoogle Scholar
• 19 Fernandez F, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. The haemor-rhagic and antithrombotic effect of dermatan sulfate. Br J Haematol 1986; 64: 309-317
  CrossrefPubMedGoogle Scholar
• 20 Ockelford PA, Carter CJ, Mitchell L, Hirsh J. Discordance between the anti Xa activity and the antithrombotic activity of an ultra-low molecular weight heparin fraction. Thromb Res 1982; 28: 401-409
  CrossrefPubMedGoogle Scholar
• 21 Walenga J, Petitou M, Lormeau JC, Samama M, Fareed J, Choay J. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb Res 1987; 46: 187-198
  CrossrefPubMedGoogle Scholar
• 22 Carrie D, Caranobe C, Boneu B. A comparison of the antithrombotic effects of heparin and of low molecular weight heparins with increasing anti-factor Xa/anti-factor Ha ratio in the rabbit. Br J Haematol 1993; 83: 622-626
  CrossrefPubMedGoogle Scholar
• 23 Carter CJ, Kelton JC, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the haemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239-1245
  PubMedGoogle Scholar